Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
Followers
Search the blog
Subscribe to my blog via email
about the author
Ulf Staginnus is a health economist with more than 15 years of international experience in health economics, pricing and market access strategies as well as competitive intelligence and health technology valuations. He is a regular speaker on pricing and health economics related matters and contributed to various articles and authored book chapters on strategy and tactics of pharmaceutical pricing and health economics. Ulf also adviced pharma, biotech and medical device companies as well as health care investors on business prospects, investment opportunities and product pricing, health outcomes as well as market access strategies.
Upcoming events
Fleming Europe
8TH ANNUAL
8TH ANNUAL
PRICING, REIMBURSEMENT & MARKET ACCESS
Biotech Investing, Funds, Venture capital
links related to health economics, biotechnology and competitive intelligence
- http://www.biospace.com
- http://www.biotechblog.com
- http://www.healtheconomics.com
- http://www.htablog.com
- http://www.pharmamarketingblog.com
- International Society for Pharmacoeconomics and Outcomes Research
- Pharma CI Conference & Exhibition
- Society for Competitive Intelligence Professionals
- Spanish Journal of Health Economics
No comments:
Post a Comment